Recently, The ASCO Post published an article titled ‘Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar'. On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to “cure” patients, in light of the fact that multiple myeloma has been turned into a chronic disease for many people. He also describes key studies he is involved in that are investigating the subject further. 

Coverage of stories discussed this week on ascopost.com:

Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar, MD

To listen to more podcasts from ASCO, visit asco.org/podcasts.

Recently, The ASCO Post published an article titled ‘Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar'. On this episode of the podcast, Dr. Rajkumar, of the Mayo Clinic, talks about what it means to “cure” patients, in light of the fact that multiple myeloma has been turned into a chronic disease for many people. He also describes key studies he is involved in that are investigating the subject further. 

Coverage of stories discussed this week on ascopost.com:

Defining Cure in Multiple Myeloma: A Conversation With S. Vincent Rajkumar, MD

To listen to more podcasts from ASCO, visit asco.org/podcasts.

On this episode, we’re reviewing recommendations from the International Association for the Study of Lung Cancer on the use of liquid biopsy for lung cancer. We’ll also hear about a study that compared two regimens added to radiotherapy for pancreatic cancer.

Coverage of stories discussed this week on ascopost.com:

Consensus Statement From IASLC on Liquid Biopsy for Advanced NSCLC

SBRT Plus Pembrolizumab/Trametinib vs Gemcitabine in Locally Recurrent Resected Pancreatic Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re reviewing the FDA full approval of a therapy for previously treated patients with advanced urothelial cancer. Then, we’ll hear about a trial that investigated potential mechanisms of acquired resistance to KRAS G12C inhibitors in patients with KRAS G12C–mutant cancers.

Coverage of stories discussed this week on ascopost.com:

FDA Grants Regular Approval to Enfortumab Vedotin-ejfv for Locally Advanced or Metastatic Urothelial Cancer

Mechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients With Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re discussing the effect of a 5- vs 2-year course of zoledronate for patients with early breast cancer; a recent FDA approval in locally advanced cutaneous squamous cell carcinoma; and a study that examined how reduced time to completion of treatment in patients with breast cancer may lead to increases in survival.

Coverage of stories discussed this week on ascopost.com:

Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer

FDA Approves Expanded Indication for Pembrolizumab in Locally Advanced Cutaneous Squamous Cell Carcinoma

Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we hear from authors who presented data on multiple myeloma, myelofibrosis, and leukemia at the European Hematology Association 2021 Virtual Congress.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we hear from authors who presented data on multiple myeloma, myelofibrosis, and leukemia at the European Hematology Association 2021 Virtual Congress.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re focusing on new research in genitourinary cancers presented at the 2021 ASCO Annual Meeting, including renal cell carcinoma and bladder cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re looking specifically at data on lung cancer presented during the 2021 ASCO Annual Meeting.

To listen to more podcasts from ASCO, visit asco.org/podcasts.

This week, we’re continuing our coverage of Plenary Presentations from the 2021 ASCO Annual Meeting, including research on adjuvant pembrolizumab for patients with renal cell carcinoma; novel treatment options for advanced esophageal squamous cell carcinoma; and adjuvant chemotherapy given after standard cisplatin-based chemoradiation for women with locally advanced cervical cancer.

To listen to more podcasts from ASCO, visit asco.org/podcasts.